share_log

There May Be Reason For Hope In Zhuhai Rundu Pharmaceutical's (SZSE:002923) Disappointing Earnings

There May Be Reason For Hope In Zhuhai Rundu Pharmaceutical's (SZSE:002923) Disappointing Earnings

珠海潤都藥業(深圳證券交易所:002923)令人失望的收益可能有理由抱有希望
Simply Wall St ·  05/04 21:41

The market was pleased with the recent earnings report from Zhuhai Rundu Pharmaceutical Co., Ltd. (SZSE:002923), despite the profit numbers being soft. We think that investors might be looking at some positive factors beyond the earnings numbers.

儘管利潤數據疲軟,但市場對珠海潤都藥業有限公司(SZSE:002923)最近的收益報告感到滿意。我們認爲,除了收益數字外,投資者可能會考慮一些積極因素。

earnings-and-revenue-history
SZSE:002923 Earnings and Revenue History May 5th 2024
SZSE: 002923 收益和收入歷史記錄 2024 年 5 月 5 日

How Do Unusual Items Influence Profit?

不尋常的物品如何影響利潤?

For anyone who wants to understand Zhuhai Rundu Pharmaceutical's profit beyond the statutory numbers, it's important to note that during the last twelve months statutory profit was reduced by CN¥41m due to unusual items. While deductions due to unusual items are disappointing in the first instance, there is a silver lining. We looked at thousands of listed companies and found that unusual items are very often one-off in nature. And that's hardly a surprise given these line items are considered unusual. Assuming those unusual expenses don't come up again, we'd therefore expect Zhuhai Rundu Pharmaceutical to produce a higher profit next year, all else being equal.

對於任何想了解珠海潤都製藥超出法定數字的利潤的人來說,值得注意的是,在過去的十二個月中,由於異常項目,法定利潤減少了4100萬元人民幣。儘管由於不尋常項目而產生的扣除首先令人失望,但有一線希望。我們調查了數千家上市公司,發現不尋常的物品本質上往往是一次性的。鑑於這些單列項目被認爲不尋常,這並不奇怪。假設這些不尋常的支出不會再次出現,因此,我們預計珠海潤都製藥明年將在其他條件下實現更高的利潤。

Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Zhuhai Rundu Pharmaceutical.

注意:我們始終建議投資者檢查資產負債表的實力。點擊此處查看我們對珠海潤都製藥的資產負債表分析。

Our Take On Zhuhai Rundu Pharmaceutical's Profit Performance

我們對珠海潤都製藥盈利表現的看法

Because unusual items detracted from Zhuhai Rundu Pharmaceutical's earnings over the last year, you could argue that we can expect an improved result in the current quarter. Because of this, we think Zhuhai Rundu Pharmaceutical's earnings potential is at least as good as it seems, and maybe even better! Unfortunately, though, its earnings per share actually fell back over the last year. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. If you want to do dive deeper into Zhuhai Rundu Pharmaceutical, you'd also look into what risks it is currently facing. To help with this, we've discovered 4 warning signs (1 doesn't sit too well with us!) that you ought to be aware of before buying any shares in Zhuhai Rundu Pharmaceutical.

由於不尋常的項目削弱了珠海潤都藥業去年的收益,你可能會爭辯說,我們可以預期本季度的業績會有所改善。正因爲如此,我們認爲珠海潤都藥業的盈利潛力至少和看起來一樣好,甚至可能更好!但不幸的是,其每股收益實際上在去年有所回落。當然,我們只是在分析其收益時才浮出水面;人們還可以考慮利潤率、預測增長和投資回報率等因素。如果你想更深入地了解珠海潤都藥業,你還需要研究它目前面臨的風險。爲了幫助解決這個問題,我們發現了 4 個警告信號(1 個對我們來說不太合適!)在購買珠海潤都藥業的任何股票之前,你應該注意這一點。

This note has only looked at a single factor that sheds light on the nature of Zhuhai Rundu Pharmaceutical's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. Some people consider a high return on equity to be a good sign of a quality business. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying.

這份報告只研究了揭示珠海潤都製藥利潤性質的單一因素。但是,如果你能夠將注意力集中在細節上,總會有更多的事情需要發現。有些人認爲高股本回報率是優質業務的好兆頭。因此,你可能希望看到這份免費收藏的擁有高股本回報率的公司,或者這份內部人士正在購買的股票清單。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論